Compare Essex Property Trust, Inc. (ESS) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Incyte Corporation — how do they compare? Essex Property Trust, Inc. trades at $269.13 (market cap $17.26B), while Incyte Corporation trades at $112.8 (market cap $22.85B). The key difference: Incyte Corporation is the larger of the two by market cap, and Essex Property Trust, Inc. pays a 3.86% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Essex Property Trust, Inc. for 111 Days and Incyte Corporation for 33 Days on average.
| ESS | INCY | |
|---|---|---|
Market Cap | $17.26B | $22.85B |
Volume | 454,464 | 1,927,029 |
Sector | Real Estate | Health |
52-Week High | $298.33 | $129.93 |
52-Week Low | $239.61 | $83.80 |
Typical Hold Time | 111 Days | 33 Days |
Enterprise Value | $23.86B | $18.35B |
Dividend Yield | 3.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $268.05, down 1.63% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly earnings, missing in Q4 2025 and Q2 2026 but beating in Q1 2026, with Q3 2026 results pending. Revenue reached $1.89B in 2025, with a net income margin of 21.48%, while valuation ratios like a P/E of 41.83 suggest a premium. Recent news highlights strong Q2 2026 results, raised guidance, and a declared dividend of $2.59 per share.
The outlook is cautiously optimistic, supported by operational strength and resolved litigation, but high valuation and earnings volatility pose risks. Analyst consensus is a Buy with a $303.41 price target, indicating potential upside, though investors should monitor debt levels and consistent earnings delivery against expectations.
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
